AU2023219133A1 - Treatment of cancer - Google Patents

Treatment of cancer Download PDF

Info

Publication number
AU2023219133A1
AU2023219133A1 AU2023219133A AU2023219133A AU2023219133A1 AU 2023219133 A1 AU2023219133 A1 AU 2023219133A1 AU 2023219133 A AU2023219133 A AU 2023219133A AU 2023219133 A AU2023219133 A AU 2023219133A AU 2023219133 A1 AU2023219133 A1 AU 2023219133A1
Authority
AU
Australia
Prior art keywords
lag
protein
derivative
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023219133A
Other languages
English (en)
Inventor
Frédéric Triebel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immutep SAS
Original Assignee
Immutep SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2201803.0A external-priority patent/GB202201803D0/en
Priority claimed from GBGB2218181.2A external-priority patent/GB202218181D0/en
Application filed by Immutep SAS filed Critical Immutep SAS
Publication of AU2023219133A1 publication Critical patent/AU2023219133A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2023219133A 2022-02-11 2023-02-10 Treatment of cancer Pending AU2023219133A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2201803.0A GB202201803D0 (en) 2022-02-11 2022-02-11 Treatment of Cancer
GB2201803.0 2022-02-11
GB2218181.2 2022-12-02
GBGB2218181.2A GB202218181D0 (en) 2022-12-02 2022-12-02 Treatment of cancer
PCT/EP2023/053381 WO2023152335A1 (en) 2022-02-11 2023-02-10 Treatment of cancer

Publications (1)

Publication Number Publication Date
AU2023219133A1 true AU2023219133A1 (en) 2024-09-05

Family

ID=85227021

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023219133A Pending AU2023219133A1 (en) 2022-02-11 2023-02-10 Treatment of cancer

Country Status (9)

Country Link
US (1) US20250368714A1 (enExample)
EP (1) EP4475955A1 (enExample)
JP (1) JP2025505738A (enExample)
KR (1) KR20240149422A (enExample)
AU (1) AU2023219133A1 (enExample)
CA (1) CA3250299A1 (enExample)
IL (1) IL314687A (enExample)
MX (1) MX2024009818A (enExample)
WO (1) WO2023152335A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025229157A1 (en) * 2024-05-01 2025-11-06 Immutep S.A.S. Combination therapy using lag-3 protein and anti-pd-1 inhibitor with radiotherapy for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
EP4157313A1 (en) * 2020-05-28 2023-04-05 Immutep S.A.S. Treatment of cancer

Also Published As

Publication number Publication date
US20250368714A1 (en) 2025-12-04
MX2024009818A (es) 2024-08-19
IL314687A (en) 2024-10-01
EP4475955A1 (en) 2024-12-18
KR20240149422A (ko) 2024-10-14
CA3250299A1 (en) 2023-08-17
JP2025505738A (ja) 2025-02-28
WO2023152335A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
KR101894689B1 (ko) 암의 치료 방법
KR102502545B1 (ko) Her2 이량체화 억제제인 페르투주맙의 용도 및 이를 포함하는 제조품
EP2968254B1 (en) Methods of treating lung cancer
JP2022536854A5 (enExample)
EP3215184B1 (en) Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis
US20250368714A1 (en) Treatment of cancer
Liu et al. Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): pre-specified interim analysis of a randomized, phase III clinical trial
US20240277804A1 (en) Triple combination therapy
CN118804760A (zh) 癌症的治疗
KR20230028321A (ko) 암의 치료
Chen et al. Anlotinib Plus Toripalimab and Nab-Paclitaxel in Patients with Locally Advanced or Metastatic Pancreatic Cancer: Study Protocol for An Open-Label, Non-Randomized, Phase II Study (ATNPA)
TW202529813A (zh) 抗體藥物共軛物ｒｉｎａｔａｂａｒｔ ｓｅｓｕｔｅｃａｎ之劑量
WO2026104573A1 (en) Lag-3 protein, pd-1 inhibitor and chemotherapy triple combination therapy
AU2013203373B2 (en) Methods of treating lung cancer
WO2026039321A1 (en) Methods for treating prostate cancer
Vasiliou et al. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2011-Focus on first-in-human and phase I trials
HK1220110B (en) Methods of treating lung cancer